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Summary To assess the clinical relevance of transforming growth factor-jl (TGF-jl) in hepatocellular carcinoma (HCC), urinary TGF-jl
and serum a-fetoprotein (AFP) were determined in 94 patients with cirrhotic HCC, 94 age- and sex-matched patients with cirrhosis alone and
50 healthy adults. TGF-,1l level in HCC was higher than in cirrhosis alone or in healthy controls (each P = 0.0001). There is an inverse
correlation between TGF-j1 and AFP levels (r = -0.292, P = 0.004). Significantly higher TGF-p1 level was found in HCC patients with
worsening Child-Pugh stages, diffuse HCC, tumour size 2 3 cm, multilobular tumour and AFP < 20 ng ml-'. TGF-j1 level decreased after
complete treatment with transcatheter arterial chemoembolization (P= 0.0001). The median survival in HCC patients with raised TGF-j1 was
shorterthan those with normal TGF-,lB (P= 0.018). Multivariate analysis indicated thatTGF-p1 and AFP were significantly correlated with the
presence of HCC. In addition, TGF-p1 could be used as a diagnostic marker for HCC, particularly in tumours with low AFP production. In
conclusion, elevated urinary TGF-j1 level is a tumour marker and predictor of poor survival for cirrhotic HCC.
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Transforming growth factor-P1 (TGF-j1) is a homodimeric
polypeptide involved in the regulation of growth and differentia-
tion of both normal and transformed cells (Roberts et al, 1988;
Roberts and Sporn, 1990; Fausto et al, 1991). It stimulates the
synthesis ofextracellular matrix formation, resulting in the forma-
tion offibrosis and tissue repair (Roberts and Sporn, 1990; Bissell
and Maher, 1996). It is supposed to be the mediator of fibrosis in
liver cirrhosis (Bissell and Maher, 1996). Previous study indicates
the expression of TGF-,11 messenger RNA in perisinusoidal and
mesenchymal cells in cirrhotic nodules and fibrous septa (Bedossa
et al, 1995). TGF-j1 inhibits the growth of most epithelial cells,
including hepatocytes (Roberts et al, 1988; Roberts and Sporn,
1990). Overexpression of the TGF-,B1 gene has been reported in
transformed or malignant-derived cells and human malignancies
(Ito et al, 1990, 1991; Roberts and Sporn, 1990; Shirai et al, 1992,
1994; Bedossa et al, 1995). Recently, elevated levels of TGF-3
mRNA and its polypeptide in tissue and plasma ofhuman hepato-
cellular carcinoma (HCC) have been reported (Ito et al, 1990,
1991; Shirai et al, 1992, 1994). The plasma TGF-j1 level
decreased significantly after successful treatment (Shirai et al,
1992, 1994). These data imply that HCC may produce TGF-j31.
Transforming growth factors have been described in the urine of
healthy adults and patients (Sherwin et al, 1983; Nishimura et al,
1986; Ranganathan et al, 1987; Yeh et al, 1987; Chuang et al,
1991, 1994; Coupes et al, 1994). Transforming growth factor
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alpha can serve as a tumour marker and as a marker for malignant
potential (Yeh et al, 1987; Lee et al, 1992; Chuang et al, 1994).
However, the clinical significance of TGF-ji1 in the urine of
patients with HCC has never been elucidated. In this study, we
determined TGF-j1 by radioimmunoassay in urine of patients
with cirrhotic HCC and correlated TGF-j1 levels with clinico-
pathological features.
PATIENTS AND METHODS
Study population
The study population comprised 94 non-alcoholic consecutive
cirrhotic HCC patients and 94 sex-matched and age-matched
(± 5 years) patients with cirrhosis alone. Cirrhosis was diagnosed
by liver biopsy, abdominal sonography (portal systemic shunts,
splenomegaly, spotty coarse parenchyma, nodular surface and dull
or round edge), biochemical evidence of parenchymal damage
plus endoscopic oesophageal or gastric varices (Tsai et al, 1993,
1994a). Patients were classified into the three Child-Pugh's
grades based on their clinical status (Pugh et al, 1973). HCC was
diagnosed by liver biopsy or aspiration cytology. There is no
previous history of specific treatment (such as interferon or anti-
cancer therapy) in patients with cirrhosis alone or patients with
HCC. Urinary samples collected before treatment were used for
determination ofTGF-j1. Clinical staging ofHCC was according
to those ofthe American Joint Committee on Cancer (1992). Table
1 shows the clinical characteristics of the patients. Another 50
community healthy adults, negative for hepatitis B surface antigen
(HBsAg) and antibodies to hepatitis C virus (anti-HCV), were
enrolled as healthy controls. Thirty-nine ofthem were men and the
other 11 were women. Their ages ranged from 28 to 67 (median
55) years. There were no significant differences in median age and
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Table 1 Clinical profiles in HCC patients and patients with cirrhosis alone
HCC Cirrhosis P-value
(n= 94) (n= 94)
Sex (M/F) 76/18 76/18 NS
Age (years) 58 (29-72)a 55 (28-67) NS
HBsAg+ (%) 71.3 74.4
Anti-HCV+ (%) 27.6 24.4
Child-Pugh grades NS
A 36 41
B 38 29
C 20 24
Clinical stage of HCCb
Stage 10
Stage II 43
Stage III 10
Stage IVA 17
Stage IVB 14
AFP (ng ml-') 155 (3-965 000) 4 (3-107) 0.0001
< 20 33 81
21-399 16 13
> 400 45 0
aContinuous data are expressed as median with ranges in parentheses.
bStaging according to the criteria of American Joint Committee on Cancer
(1992). HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen;
Anti-HCV, antibodies to hepatitis C virus; AFP, a-fetoprotein.
sexual distribution among these three groups. There was no space-
occupying lesion in patients with cirrhosis alone and healthy
controls as evidenced by normal abdominal sonography. All
healthy controls have normal serum transaminase and creatinine
levels. All the patients and controls were enrolled during the same
period and all gave informed consent to participate in the study,
which was approved by the Investigation and Ethics Committee of
the hospital.
Urine collection and preparation
The extraction ofTGF-P1 from urine was modified from methods
described previously (Sherwin et al, 1983). Spot urine (10 ml) in
the early moruing was collected and kept at 4°C. Urine specimens
were acidified with acetic acid (Sigma, St Louis, MO, USA) to a
final concentration of 1 M. The resulting precipitate of acid insol-
uble materials was removed by centrifugation at 800 g for 30 min
at 4°C. Acidified supermatants were applied to Sep-Pak C18
cartridges (Waters, Milford, MA, USA) equilibrated with 60%
acetonitrile (Sigma) containing 0.1% trifluoroacetic acid (TFA;
Sigma). After loading the urine, the cartridge was washed slowly
(1 ml min-') with 20 ml of 0.1% TFA. TGF-,1 was eluted with
60% acetonitrile containing 0.1% TFA. The extracted material was
lyophilized, dissolved in 1 ml of 1 M acetic acid. The concentrated
samples were stored at - 70°C until used.
Radioimmunoassay forTGF-f1
TGF-,B1 was determined with aTGF-P[I '251-radioimmunoassay kit
(El du Pont de Nemours, Boston, MA, USA). The recovery of
native TGF-PI is greater than 90%. The sensitivity of the assay
is approximately 0.27 ng ml-'. The working range is between
0.3 ng ml-' and 20 ng ml-'. The assay is highly specific, without
cross-reaction with human and porcine TGF-P 2, chicken TGF-j
3, basic fibroblast growth factor and interleukins. Briefly, 10gl of
1.2 N HCl (Sigma) was added to 100 ,ul ofprepared urine sample.
After mixing thoroughly by vortexing, the specimen was incu-
bated at room temperature for 15 min. Then the specimen was
neutralized by addition of 20 pl of 0.5 M Hepes (N-[2-hydroxy-
ethyl]piperazine-N'-[2-ethanesulphonic acid]) (Sigma)/0.72 M
sodium hydroxide (Sigma). The pH was adjusted to be around
7.0-8.0. After mixing thoroughly by vortexing, 100 gl of the
prepared specimens (or different concentrations of standard TGF-
P1) were added to 100 gl of anti-human TGF-j1 antibody. The
mixture was mixed and incubated at room temperature for 6 h.
One hundred microlitres of['25I]TGF-P1 was added and incubated
at room temperature for 18 h. After adding 100 ,ul of second anti-
body, the mixture was incubated for 1 h at room temperature.
Then, the tubes were centrifuged at 2200g at 4°C for 30 min.
Radioactivity in the pellet was counted in a gamma counter.
Urinary creatinine, determined by autoanalyser, was used to
normalize the urinary TGF-[1 level. The final concentration of
TGF-1 was expressed as ig g-' creatinine. The coefficients of
variation of intra-assay and interassay were 7.5% and 10.0%
respectively.
Serological examination
HBsAg, anti-HCV and a-fetoprotein (AFP) were tested with
Ausria-II, second-generation HCV enzyme immunoassay (EIA)
and a-feto RIABEAD (Abbott Laboratories, Chicago, IL, USA)
respectively. For anti-HCV, reactive specimens were retested.
Repeatedly reactive samples were tested with another second-
generation anti-HCV immunoassay (UBI HCV EIA; United
Biomedical, Lake Success, NY, USA), which incorporates
synthetic peptides from the capsid and non-structural protein
region as the solid-phase antigen. Only specimens reactive in all
three tests were considered as anti-HCV positive. Conventional
liver function tests and creatinine level were determined with an
autoanalyser.
Transcatheter arterial chemoembolization (TACE)
TACE was performed according to the procedure described previ-
ously (Hsieh et al, 1996). A complete TACE was defined as: (1) all
feeding arteries including collateral vessels were completely
embolized angiographically; (2) serum AFP level decreased after
TACE by more than 75% compared with the pre-TACE level; and
(3) > 50% reduction in tumour size as evaluated by image study
(sonography or computerized tomography) 1 month after TACE
(Hsieh et al, 1996).
Follow-up
The starting time of survival analysis was the day of diagnosis of
HCC. All prognostic variables were measured on that day. The
survival and the date ofdeath were determined in December 1994
by review of clinical records, telephone or by consultation of
population registries.
Statistical analysis
Survival was expressed as median ± standard error, whereas other
continuous data were expressed as median with ranges in paren-
theses. The difference between the unpaired continuous variables
wascompared with theMann-Whitney U-testorthe Kruskal-Wallis
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Figure 1 Boxplot of urinary TGF-jl1 level in patients with HCC and cirrhosis
and in healthy controls. The horizontal line inside the box represents the
median level. The lower and upper boundary represent the 25th and the
75th percentile of data respectively. TGF-,lB level in HCC was higher than
that in cirrhosis or controls (each P= 0.0001; Mann-Whitney U-test). TGF-,B1
level in cirrhosis was higher than that in controls (P= 0.0001; Mann-Whitney
U-test)
Table 2 Risk for HCC evaluated by stepwise logistic regression analysis of
the comparison between HCC patients and patients with cirrhosis alonea
Variables Regression Standard P-value Odds ratio
coefficient error (95% Cl)
TGF-,1 0.082 0.020 0.0001 1.08 (1.04-1.12)
AFP 0.064 0.020 0.001 1.06 (1.02-1.10)
ALT -0.014 0.006 0.030 0.98 (0.97-0.99)
ALP 0.038 0.013 0.005 1.03 (1.01-1.06)
aDependent variable: existence of HCC. Independent variables: urinary
TGF-,lB, serum AFP, sex, age, serum albumin, globulin, aspartic
aminotransferase, ALT, bilirubin (direct and indirect), ALP and y-glutamyl
transpeptidase. HCC, hepatocellular carcinoma; AFP, a-fetoprotein; TGF-,Bl,
transforming growth factor-,8l. ALT, alanine aminotransferase; ALP, alkaline
phosphatase; Cl, confidence interval.
one-way analysis ofvariance when appropriate. The Spearman rank
correlation was used to calculate the relationship between contin-
uous variables. The difference between paired continuous data was
compared with the Wilcoxon signed-rank test. Chi-square test with
Yates' correction was used to compare differences between propor-
tions. Stepwise logistic regression was used for multivariate
analysis. Odds ratio (OR) with 95% confidence interval (95% CI)
was used to estimate causal relations between risk factors and
exposure. The cumulative survival rate was determined using the
product-limited (Kaplan-Meier) estimate (Kaplan and Meier, 1958),
and a comparison of survival curves was made using the log-rank
test. Forevaluating the diagnostic performance ofAFP andTGF-p31,
we calculated the sensitivity, specificity, positive and negative
predictive value, positive and negative likelihood ratio and diag-
nostic accuracy according to previous methods (Sox et al, 1989).
The recommended diagnostic cut-offvalue ofAFP was 400 ng ml'
(Sherlock and Dooley, 1993; Colombo, 1995). For TGF-01, we
used the receiver operating characteristic (ROC) curve to select
the optimal cut-off value (Swets, 1988). The ROC curve was
constructedby calculating the sensitivity and specificity ofthe TGF-
f1 assay at several cut-offpoints. The cut-offvalue with the highest
accuracy was selected as the diagnostic cut-off point. If more than
one cut-off value showed the same accuracy, the cut-off value with
nearly equal sensitivity and specificity was chosen. The differences
in diagnostic accuracy between the marker tests were measured
using McNemar's X2-test. Two-tailed P-values and 95% CI were
given when appropriate. An alpha of0.05 was used as the indicator
ofstatistical significance.
RESULTS
Urinary TGF-,1 and serum AFP levels in patients and
healthy controls
The recovery ofthe acid precipitation method for urinaryTGF-PI
was greater than 85% (data not shown). As shown in Figure 1, the
urinary TGF-,l level in patients with HCC (median 61.1, range
3.5-184.0 jg g-1 creatinine) was significantly higher than in
cirrhotic patients alone (median 30.3, range 4.3-52.5 gg g-' creati-
nine; P = 0.0001) or in healthy controls (median 12.2, range
1.5-33.6 ,ug g-1 creatinine; P = 0.0001). The median level of
urinary TGF-P1 in patients with cirrhosis alone was also statisti-
cally higher than that ofhealthy controls (P = 0.0001).
The upper limit of normal urinary TGF-,B1 level was defined
as values greater than the 95th percentile of healthy controls
(32.3 jig g-1 creatinine). Raised urinary TGF-P1 levels were noted
in 58 (61.7%) of HCC patients and 46 (48.9%) of patients with
cirrhosis alone. There is an inverse correlation between TGF-,B1
and logAFP (r = - 0.292, P = 0.004).
The upper limit of normal AFP level was defined as 20 ng ml-1
(Sherlock and Dooley, 1993), whereas the recommended diag-
nostic cut-off value for HCC was 400 ng ml-1 (Colombo, 1995).
Serum AFP level less than 20 ng ml-' was noted in all healthy
controls, 81 (86.1%) patients with cirrhosis alone and 33 (35.1%)
patients with HCC. There were 45 (47.8%) HCC patients with
AFP levels greater than 400 ng ml (Table 1). As shown in Table
1, the median level ofserum AFP in patients with HCC was higher
than that in cirrhotic patients alone (P = 0.0001) or in healthy
controls (median 4, range 3-10 ng ml-'; P = 0.0001).
Association between levels of TGF-f1 and AFP and
presence of HCC
Multivariate analysis was used to adjust for the possible
confounding effects of sex, age and impaired liver function tests
on the levels of urinary TGF-31 and serum AFP in patients with
HCC. Both TGF-5l (OR 1.08, 95% CI 1.04-1.12, P = 0.001) and
AFP (OR 1.06, 95% CI 1.02-1.10, P = 0.001) were found to be
associated, in a dose-related fashion, with an increased risk for the
presence ofHCC (Table 2).
TGF-p1 and AFP as tumour markers for HCC
The selected optimal cut-off value using the ROC curve was
50 jig g-' creatinine for TGF-p1. TGF-P1 levels greater than
selected cut-offpoints were found in 53.1% (50 of 94) of patients
with HCC, 1.1% (1 of94) ofpatients with cirrhosis alone and none
of the healthy controls. This cut-off value gave a specificity of
98.9% at sensitivity of 53.1%. The calculated diagnostic accuracy,
positive and negative predictive values and positive and negative
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Figure 2 Urinary TGF- 1 level before and after complete treatment with
transcatheter arterial chemoembolization in HCC patients (P = 0.0001;
Wilcoxon signed-rank test). The vertical bar indicates the median level of
TGF-,B1. TACE: transcatheter arterial chemoembolization
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Figure 3 Cumulative survival curves using the status of urinary TGF-01
levels in patients with HCC. Increased TGF-,1 levels were defined as those
values greater than the 95th percentile of healthy controls. The median
survival in 58 patients with raisedTGF-p1 levels (-0-) was shorter than in
36 patients with normal TGF-,B1 levels (-*-) (P= 0.018; Kaplan-Meier
method with log-rank test)
Table 3 UrinaryTGF-p1 level in relation to clinical features in HCC patients
Parameters Group n TGF-pl (,Ug g-t creatinine) P-value
Sex
Male 76 58.6 (3.5-164.3)a NS
Female 18 66.4 (5.0-184.0)
Age (years)
< 40 14 69.7 (12.0-164.3) NS
> 40 80 58.6 (3.5-184.0)
Child-Pugh
A 36 23.7 (5.0-105.0)b,c 0.0001
B 38 55.1 (5.0-184.0)bd
C 20 123.7 (3.5-182.5)c.d
HBsAG/anti-HCV
Neg./neg. 10 30.8 (5.0-98.4) NS
Pos./neg. 58 63.2 (5.0-182.5)
Neg./pos. 17 45.8 (3.5-184.0)
Pos./pos. 9 65.3 (11.0-117.9)
Metastasis
Yes 11 30.2 (8.0-142.3) NS
No 83 63.4 (3.5-184.0)
PVT
Yes 30 59.1 (5.0-182.5) NS
No 64 61.1 (3.5-184.0)
Location
Single lobe 52 33.2 (5.0-164.3) 0.004
Multiple lobes 42 67.9 (3.5-184.0)
AFP
< 20 ng ml-' 33 66.4 (6.0-184.0) 0.024
> 20 ng ml-' 61 36.4 (3.5-153.0)
Clinical stage
10 17.5 (6.0-107.0)e
11 43 61.8 (5.0-124.0)f
III 10 65.3 (5.0-164.3)
IVA 17 70.2 (3.5-187.4)ef
IVB 14 41.8 (6.0-142.3)
aData are expressed as median with ranges in parentheses. bp= 0.027 (Mann-Whitney U-test). cdp = 0.0001 (Mann-Whitney U-test).
ep = 0.01 (Mann-Whitney U-test). fP = 0.02 (Mann-Whitney U-test). HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen;
PVT, portal vein thrombosis; anti-HCV, antibodies to hepatitis C virus; pos., positive; neg., negative.
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Table 4 Urinary TGF-,lB levels in relation to echographic type and tumour
size
Type and size of HCC TGF-j31 (,Ug g-' creatinine)
Diffuse (n = 30) 96.5 (3.-5184.0)a,b
Non-diffuse (n = 64) 33.3 (5.0-164.3)b
< 3 cm (n = 19) 17.0 (5.0-112.3)c,d
3-5 cm (n = 24) 36.4 (5.0-143.3)ce
> 5 cm (n = 21) 56.9 (5.0-164.3)d,e
aData were expressed as median with ranges in parentheses. bp = 0.001
(Mann-Whitney U-test). c,d,ep < 0.02 (Kruskal-Wallis one-way analysis of
variance). HCC, hepatocellular carcinoma; TGF-,1, transforming growth
factor ,B1.
likelihood ratios were 76.0%, 98.0% and 67.8%, and48.2 and 0.47
respectively. On the otherhand, the recommended diagnostic level
ofAFP forHCC was 400 ng ml-' (Colombo, 1995). Using this cut-
off value, the sensitivity was 47.8% with a specificity of 100%.
The calculated diagnostic accuracy, positive and negative predic-
tive values and positive and negative likelihood ratios were 73.9%,
100% and 65.7%, and 47.8 and 0.52 respectively. No matter which
marker was used, there was no statistically signiflcant difference
between diagnostic accuracies.
When both AFP and TGF-jI1 were determined in parallel, 30
(61.2%) of 49 HCC patients with AFP < 400 ng ml' could be
diagnosed. Both the sensitivity (79.7%) and diagnostic accuracy
(81.3%) increased without decreasing the specificity (98.9%). The
resulting positive and negative likelihood ratios were 74.5 and 0.2
respectively. It is ofnote that the diagnostic accuracy ofusing both
AFP and TGF-01 as markers was significantly higher than when
using either marker alone (P < 0.001; McNemar's X2-test).
UrinaryTGF-01 level before and after complete TACE
To assess the effect oftherapy on the TGF-P1 level, we randomly
chose 10 HCC patients with raised TGF-PI levels for comparison.
All these patients were defined as having complete TACE after
therapy. As shown in Figure 2, the median urinary TGF-,B1 level
after TACE (45.5 ,ug g-' creatinine) was significantly lower than
that (100.5 ,ug g-I creatinine) before TACE (P = 0.0001; Wilcoxon
signed-rank test). In another 10 patients without complete TACE,
there was no significant difference in the TGF-B1 level before and
after TACE (data not shown). Regardless of whether the TACE
treatment was effective, TGF-B1 level increased as tumours
recurred or increased in size during follow-up (data not shown).
Urinary TGF-f1 level in relation to HCC survival
As shown in Figure 3, the median survival (169 ± 21, 95% CI
128-210 days) in 36 patients with normal TGF-P1 levels was
significantly longer than that (86 ± 23, 95% CI 40-132 days) in 58
patients with elevated TGF-131 levels (P = 0.018, Kaplan-Meier
method with log-rank test).
Clinical relevance of urinary TGF-f1 level in patients
with HCC
As shown in Table 3, the TGF- 1 levels in patients with
Child-Pugh C were higher than those in Child-Pugh B or
Child-Pugh A (each P = 0.0001). Significantly elevated TGF-PI
levels were found in patients with an area of tumour involvement
of more than one lobe (P = 0.004). TGF-pI levels in patients with
normal AFP levels (< 20 ng ml') were higher than those in
patients with higher AFP levels (P = 0.024; Table 3). Compared
with patients with non-diffuse HCC, patients with diffuse HCC
had higher urinary TGF-P1 levels (P = 0.001; Table 4). Among
non-diffuse HCC, TGF-Pl levels in patients with tumour size
< 3 cm were lower than those with larger tumour size (P < 0.02;
Table 4). There was a positive correlation between TGF-,I level
and clinical stage of patients with HCC (r = 0.178, P < 0.05). As
shown in Table 3, TGF-131 levels in HCC patients with stage IVA
were higher than in patients with stage I (P = 0.01) or in patients
with stage II (P = 0.02). There was no statistical difference in
TGF-,B1 level with regard to sex, age, status of HBsAg and anti-
HCV, extrahepatic metastasis or portal vein thrombosis (Table 3).
DISCUSSION
Urinary TGF-1 in man may reflect normal excretion of the
polypeptide by the urinary tract. It could also reflect the produc-
tion of TGF-PI elsewhere in the body and being filtered by the
glomeruli or being produced lower in the urinary tract. Although
we did not determine plasma TGF-,B1 level, there was no relation-
ship between plasma TGF-4 level and renal function (Coupes et
al, 1994). In this study, we still use urinary creatinine to normalize
the TGF-13I concentration. It is worth noting that the larger the
tumour size, the higher the urinary TGF-,B1 level (Table 4).
Moreover, the significantly lower urinary TGF-i1 level after
complete TACE therapy (Figure 2) suggested that TGF-PI level
might be related to tumour mass. Decreased plasmaTGF-P1 level
after successful anti-cancer treatment has also been reported
previously (Shirai et al, 1992, 1994). These observations indicated
that both urinary and plasma TGF-,B1 levels might reflect liver
tissue TGF-,B1.
Liver is the major site of clearance and metabolism of biologi-
cally active TGF- Il (Roberts and Sporn, 1990; Fausto et al, 1991).
Raised TGF-11 level may be caused by increased production
and/or decreased clearance. An increased TGF-P1 production has
been reported after hepatectomy and in some liver disease (Ito et
al, 1990, 1991; Roberts and Spom, 1990; Shirai et al, 1992, 1994;
Bedossa et al, 1995). In this study, the raised TGF-P1 levels in
patients with cirrhosis alone might be caused by impaired liver
function (Figure 1). Elevated urinary TGF-1I levels in patients
with cirrhotic HCC might be due to decreased clearance and/or
increased production. The association between raised TGF-31
level and worse Child-Pugh grades in patients with cirrhotic HCC
(Table 3) and patients with cirrhosis alone (data not shown)
suggested the contribution of impaired liver function. After
adjusting for the possible confounding effects caused by impaired
liver function, our results indicate that urinary TGF-,B1 level is
significantly associated, in a dose-related fashion, with the pres-
ence ofHCC (Table 2). In addition, largertumours were frequently
associated with higherTGF-01 levels (Table 4). The significantly
decreased TGF-l1 levels after complete TACE treatment in
patients with HCC (Figure 2) also implies that TGF-4I might be
related to tumour mass and that raised TGF-j1 levels in HCC were
caused by increased production. On the other hand, the inverse
relationship between raised urinary TGF-,B1 level and survival
(Figure 3) suggests thatTGF-1 might be a predictorofpoor prog-
nosis of HCC.
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How TGF-j is involved in the growth control of HCC remains
unclear. Given the inhibitory effects of TGF-4 in the normal and
neoplastic hepatocytes, it is logical to expect that absence of the
factor or a loss of sensitivity to TGF-P could contribute to cell
transformation (Fausto et al, 1991). However, the discrepancy
between the increase in TGF-f level in HCC and the highly
proliferating cell rate in HCC suggests that HCC cells have lost
autocrine growth inhibition of TGF-1 during malignant transfor-
mation (Roberts et al, 1988; Roberts and Sporn, 1990; Bedossa et
al, 1995). The escape of tumoral hepatocytes from the control of
cell mito-inhibition by TGF-pl, despite its overexpression by
these cells, might be related to secretion ofbiologically inactive or
latent TGF-3 and to the absence of or lower numbers of TGF-1
receptors on the plasma membrane of malignant hepatocytes
(Roberts et al, 1988; Fausto et al, 1991; Bedossa et al, 1995).
Increased secretion ofTGF-1 by cancer cells that have lost respon-
siveness to its growth inhibitory activities is thought to facilitate
tumour progression by indirect means, such as suppression of
immune surveillance and stimulation of tumour stroma (Roberts
et al, 1988; Roberts and Sporn, 1990; Fausto, 1991; Fausto et al,
1991). Tumour cells might indirectly support their growth by
paracrine action ofthe TGF-4 on the supporting stromal elements.
By extracellular matrix formation and angiogenesis, the conse-
quent neovascularization removes the limitations of diffusion
through solid tissues (Roberts et al, 1988; Fausto, 1991). This in
turn results both in a rapid increase in tumour size and provision of
a route for metastasis throughout the body. Moreover, TGF-3 not
only stimulates the synthesis of tumour stromal elements but also
creates a selective environment in which 'partly transformed' cells
with defective TGF-P response can proliferate and form tumours
(Roberts et al, 1988; Fausto, 1991). In terms ofa model forTGF-f
action in carcinogenesis, it is known that most tumour cells
express TGF-f mRNA and that many secrete TGF-j (Ito et al,
1990, 1991; Fausto, 1991; Fausto et al, 1991; Shirai et al, 1992,
1994; Bedossa et al, 1995). Such growth factor secretion might
result in stimulation of the growth of the tumour with accom-
panying stimulation of the development of supporting tumour
stromal elements. On the other hand, although we give no indica-
tion ofcellular source ofTGF-f in our patients, the cellular source
ofTGF-P in patients with cirrhotic HCC has been well studied by
Bedossa et al (1995). Besides in HCC cells, TGF-f mRNA and
TGF-, did exist in extracellular matrix along the fibrous septa.
Hence, TGF-3 may actually derive from tumour stroma and thus
may be an indicator of tumour desmoplasia or may correlate with
tumour necrosis.
HCC appears to be associated with hepatitis B and C viral infec-
tion and is common in patients with cirrhosis caused by chronic
viral hepatitis (Jeng and Tsai, 1991; Tsai et al, 1994a-c, 1996).
Cirrhosis is considered to be a premalignant lesion of HCC
(Sherlock and Dooley, 1993; Tsai et al, 1994a-c, 1996); thus, it is
important to diagnose HCC in cirrhotic patients. Among various
serological markers developed for diagnosis of HCC, AFP is one
of the most intensively studied tumour markers (Sherlock and
Dooley, 1993; Chuang et al, 1994; Colombo, 1995; Tsai et al,
1995). As shown in this study, an AFP level less than the recom-
mended diagnostic level (400 ng ml-') was noted in 52.1.% (49 of
94) of HCC patients at the time oftumour detection. Furthermore,
at least one-third of small HCC and up to 30% of advanced HCC
will be missed unless other diagnostic tools are used (Sherlock
and Dooley, 1993; Tsai et al, 1994b, 1995; Colombo, 1995). In
addition, AFP may be elevated in non-malignant liver disease
(Sherlock and Dooley, 1993; Colombo, 1995; Tsai et al, 1995). It
is obvious that AFP alone is not a reliable indicator for the detec-
tion of HCC in patients with a low AFP value. On the other hand,
the main problem regarding the diagnosis of HCC is that ofdetec-
tion of tumour presence in those cirrhotic patients in whom the
AFP is raised but diagnostic. Therefore, additional and more sensi-
tive diagnostic tools must be sought.
In this study, we have demonstrated that urinary TGF-P1 might
be used as a tumour marker for HCC. After comparing the diag-
nostic performance of AFP and TGF-.1, either marker showed a
good specificity, moderate sensitivity and high positive likelihood
ratio. There was no significant difference between their diagnostic
accuracies. Moreover, determination of AFP and TGF-3 1 in
parallel significantly improved the diagnostic accuracy and sensi-
tivity without decreasing the specificity. Although each test may
not have sufficient sensitivity, the simultaneous use of both tests
may be highly discriminatory in the detection of HCC. However,
parallel detection of both markers increases the number of tests
performed, which is likely to have cost implications. Hence, we
suggest that assay for urinary TGF-P1 should be performed to
improve the detection ofHCC with low AFP production. It is note-
worthy that AFP is an oncofetal protein produced by HCC.
Although the AFP gene was re-expressed in hepatoma cells, TGF-
1 may repress the AFP gene expression in hepatoma cells (Nakao
et al, 1991). Our results also show a reverse relationship between
levels of serum AFP and urinary TGF- 1. The urinary TGF- I
level in HCC patients with normal AFP level was statistically
higher than that in patients with raised AFP (Table 3). This signif-
icant inverse trend still existed even when the higher cut-off value
of AFP (100 or 400 ng ml-') was used (data not shown). This
observation also favours the use of urinary TGF- 1 as a comple-
mentary tumour marker for the detection of HCC in AFP-non-
producing tumours.
In conclusion, this study shows that urinary TGF-PI level
increases in patients with cirrhotic HCC. Raised urinary TGF-f1
level can be used as a tumour marker for HCC. It is also a
predictor ofpoor survival in HCC.
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